Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

NCT00577356 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Safety reasons, though no safety issues arose.

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
BIOLOGICAL: CG1940/CG8711

Sponsor

Benaroya Research Institute

Collaborators

[object Object]
[object Object]